Table 1 Baseline characteristic

From: Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial

Characteristics

All patients (n = 40)

Age, years, median (range)

60 (40–73)

< 65

29 (72.5)

≥ 65

11 (27.5)

Male

36 (90.0)

Eastern Cooperative Oncology Group PS

0

9 (22.5)

1

31 (77.5)

Smoking status

Never

2 (5.0)

Current/Former

38 (95.0)

Basic disease

Chronic obstructive pulmonary disease

16 (40.0)

Hepatitis B

2 (5.0)

Hemoptysis

1 (2.5)

Others

21 (52.5)

Anatomical type

Central

33 (82.5)

Peripheral

7 (17.5)

Vascular invasion grade

Grade 1

6 (15.0)

Grade 3

29 (72.5)

NA

5 (12.5)

Disease stage

IV

40 (100.0)

Brain metastases

Yes

6 (15.0)

No

34 (85.0)

Liver metastases

Yes

7 (17.5)

No

33 (82.5)

Number of metastatic organs

1

17 (42.5)

≥ 2

23 (57.5)

dNLR

≤ 3

32 (80.0)

> 3

8 (20.0)

Lactate dehydrogenase

≤ Upper limit of normal

16 (40.0)

> Upper limit of normal

19 (47.5)

Unknown

5 (12.5)

  1. Data are n (%). dNLR derived neutrophil-to-lymphocyte ratio, NA not assessable